<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="correction" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ophthalmol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Ophthalmol Ther</journal-id><journal-title-group><journal-title>Ophthalmology and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8245</issn><issn pub-type="epub">2193-6528</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35941337</article-id><article-id pub-id-type="pmc">PMC9437156</article-id><article-id pub-id-type="publisher-id">553</article-id><article-id pub-id-type="doi">10.1007/s40123-022-00553-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Correction to: Expert Consensus on the Use of the PRESERFLO&#x02122; MicroShunt Device in the Treatment of Glaucoma: A Modified Delphi Panel</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Khawaja</surname><given-names>Anthony P.</given-names></name><address><email>anthony.khawaja@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stalmans</surname><given-names>Ingeborg</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Aptel</surname><given-names>Florent</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Barton</surname><given-names>Keith</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Beckers</surname><given-names>Henny</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Klink</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Marchini</surname><given-names>Giorgio</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez de la Casa</surname><given-names>Jose</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Simonsen</surname><given-names>Jan H.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>T&#x000f6;teberg-Harms</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Vass</surname><given-names>Clemens</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Abeg&#x000e3;o Pinto</surname><given-names>Lu&#x000ed;s</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>NIHR Biomedical Research Centre, </institution><institution>Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, </institution></institution-wrap>London, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.410569.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0626 3338</institution-id><institution>Department of Ophthalmology, </institution><institution>University Hospitals UZ Leuven, </institution></institution-wrap>Leuven, Belgium </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.5596.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0668 7884</institution-id><institution>Research Group Ophthalmology, </institution><institution>Catholic University KU Leuven, </institution></institution-wrap>Leuven, Belgium </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.410529.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0792 4829</institution-id><institution>Clinique Universitaire d&#x02019;Ophtalmologie, CHU de Grenoble-Alpes, </institution></institution-wrap>Grenoble, France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.412966.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0480 1382</institution-id><institution>University Eye Clinic, Maastricht University Medical Center+, </institution></institution-wrap>Maastricht, The Netherlands </aff><aff id="Aff6"><label>6</label>Herzog Carl-Theodor Eye Hospital, Munich, Germany </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.411475.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1756 948X</institution-id><institution>Department of Neurosciences, Biomedicine and Movement, Eye Clinic and UOC Oculistica, </institution><institution>University Hospital and AOUI, </institution></institution-wrap>Verona, Italy </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.411068.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0671 5785</institution-id><institution>Hospital Universitario Clinico San Carlos, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.27530.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0646 7349</institution-id><institution>Department of Ophthalmology, </institution><institution>Aalborg University Hospital, </institution></institution-wrap>Aalborg, Denmark </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.412004.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0478 9977</institution-id><institution>Department of Ophthalmology, </institution><institution>University Hospital Zurich, </institution></institution-wrap>Zurich, Switzerland </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.410427.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2284 9329</institution-id><institution>Department of Ophthalmology, Medical College of Georgia, </institution><institution>Augusta University, </institution></institution-wrap>Augusta, GA USA </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Department of Ophthalmology and Optometry, </institution><institution>Medical University Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.411265.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2295 9747</institution-id><institution>Department of Ophthalmology, </institution><institution>Hospital Santa Maria, </institution></institution-wrap>Lisbon, Portugal </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2022</year></pub-date><volume>11</volume><issue>5</issue><fpage>1767</fpage><lpage>1773</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2022</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><related-article related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.1007/s40123-022-00529-4" id="d32e85"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2022</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Correction to: Ophthalmol Ther 10.1007/s40123-022-00529-4</title><p id="Par1">For the statement in Table 1, &#x0201c;In addition to patients with primary open-angle glaucoma, the PRESERFLO&#x02122; MicroShunt device may also be used in patients with pseudoexfoliation (off-label), in line with conventional filtering surgery&#x0201d; it should be &#x0201c;Agree (82) Disagree (0)&#x0201d; and NOT &#x0201c;Disagree (82) Agree (9)&#x0201d;. The corrected Table <xref rid="Tab1" ref-type="table">1</xref> is given below.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Responses to statements on patient selection and preoperative considerations</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Likert scale</th><th align="left">Consensus agreement/disagreement</th><th align="left">Percentage agreement/disagreement (%)<sup>a</sup></th><th align="left">Delphi questionnaire round</th></tr></thead><tbody><tr><td align="left">The PRESERFLO&#x02122; MicroShunt can be used in patients with primary open-angle glaucoma to reduce or manage IOP levels</td><td align="left">Agreement</td><td align="left">100</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">The PRESERFLO&#x02122; MicroShunt is effective at reducing IOP in patients with high-tension primary open-angle glaucoma (IOP&#x02009;&#x0003e;&#x02009;21&#x000a0;mmHg)</td><td align="left">Agreement</td><td align="left">100</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left" colspan="4">The PRESERFLO&#x02122; MicroShunt is beneficial for patients with primary open-angle glaucoma:</td></tr><tr><td align="left">&#x000a0;Receiving the maximum tolerated dose of glaucoma medication(s) with insufficient IOP control</td><td align="left">Agreement</td><td align="left">100</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">&#x000a0;With progressive visual field loss</td><td align="left">Agreement</td><td align="left">91</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">&#x000a0;Demonstrating poor adherence or intolerance to topical medications with topical or systemic side effects</td><td align="left">Agreement</td><td align="left">100</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">The PRESERFLO&#x02122; MicroShunt is particularly valuable for those patients who would benefit from fewer follow-up appointments and monitoring<sup>b</sup></td><td align="left">No consensus reached</td><td align="left"><p>Agree (27)</p><p>Disagree (9)</p></td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left" colspan="4">Although the target patient population for the PRESERFLO&#x02122; MicroShunt are patients with primary open-angle glaucoma, with no other underlying eye disorders, the device can also be used in patients with the following:</td></tr><tr><td align="left">&#x000a0;Pigment dispersion (off-label)</td><td align="left">Agreement</td><td align="left">82</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">&#x000a0;Neovascular glaucoma (off-label)</td><td align="left">Disagreement</td><td align="left">82</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">&#x000a0;Well-controlled uveitis without active inflammation (off-label)<sup>c</sup></td><td align="left">No consensus reached</td><td align="left"><p>Agree (36)</p><p>Disagree (9)</p></td><td align="left">Round&#x000a0;2</td></tr><tr><td align="left">&#x000a0;Congenital glaucoma (off-label)</td><td align="left">No consensus reached</td><td align="left"><p>Agree (18)</p><p>Disagree (18)</p></td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">&#x000a0;High myopia (following satisfactory assessment of the conjunctiva)<sup>c</sup></td><td align="left">Agreement</td><td align="left">73</td><td align="left">Round&#x000a0;2</td></tr><tr><td align="left">&#x000a0;High hyperopia (providing there is sufficient anterior chamber depth)<sup>c</sup></td><td align="left">No consensus reached</td><td align="left"><p>Agree (27)</p><p>Disagree (9)</p></td><td align="left">Round&#x000a0;2</td></tr><tr><td align="left">&#x000a0;Normal-tension glaucoma with baseline IOP in the upper normal range<sup>c</sup></td><td align="left">No consensus reached</td><td align="left"><p>Agree (0)</p><p>Disagree (18)</p></td><td align="left">Round&#x000a0;2</td></tr><tr><td align="left">The PRESERFLO&#x02122; MicroShunt implantation procedure may be suitable for other forms of open-angle glaucoma, but further data are required to examine this</td><td align="left">Agreement</td><td align="left">73</td><td align="left">Round&#x000a0;2</td></tr><tr><td align="left">In addition to patients with primary open-angle glaucoma, the PRESERFLO&#x02122; MicroShunt device may also be used in patients with pseudoexfoliation (off-label), in line with conventional filtering surgery</td><td align="left">Agreement</td><td align="left"><p>Agree (82)</p><p>Disagree (0)</p></td><td align="left">Round&#x000a0;2</td></tr><tr><td align="left">To determine the suitability of patients for the PRESERFLO&#x02122; MicroShunt, previous aqueous production limiting factors (e.g. cyclodestructive procedures) should be considered, if known</td><td align="left">Agreement</td><td align="left">73</td><td align="left">Round&#x000a0;2</td></tr><tr><td align="left">The PRESERFLO&#x02122; MicroShunt implantation procedure may be performed on patients that have had previous glaucoma surgery with sub-conjunctival drainage, provided there is a quadrant with the intact conjunctiva amenable to PRESERFLO&#x02122; MicroShunt implantation</td><td align="left">No consensus reached</td><td align="left"><p>Agree (55)</p><p>Disagree (18)</p></td><td align="left">Round&#x000a0;2</td></tr><tr><td align="left">The PRESERFLO&#x02122; MicroShunt implantation procedure may be performed on patients that have had previous glaucoma surgery with sub-conjunctival drainage, provided there is a quadrant with the intact conjunctiva amenable to PRESERFLO&#x02122; MicroShunt implantation. Although the outcome is expected to be less favourable than a primary surgery, it may be considered in certain cases</td><td align="left">Agreement</td><td align="left">82</td><td align="left">Round&#x000a0;3</td></tr><tr><td align="left">To optimise surgical outcomes, eligible patients for the PRESERFLO&#x02122; MicroShunt should not have had incisional glaucoma surgery on the affected eye ideally within the last 12&#x000a0;months. Although a shorter interval is possible and sometimes necessary due to clinical need, this may be associated with less chance of success</td><td align="left">Agreement</td><td align="left">100</td><td align="left">Round&#x000a0;3</td></tr><tr><td align="left">To optimise surgical outcomes, eligible patients for the PRESERFLO&#x02122; MicroShunt should not have had cataract surgery on the affected eye ideally within the last 6&#x000a0;months. Although a shorter interval is possible and sometimes necessary due to clinical need, this may be associated with less chance of success</td><td align="left">Agreement</td><td align="left">100</td><td align="left">Round&#x000a0;3</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left">Multiple-choice</th><th align="left">Consensus</th><th align="left" colspan="2">Percentage (%)<sup>a</sup></th><th align="left">Delphi questionnaire round</th></tr></thead><tbody><tr><td align="left">To optimise surgical outcomes, eligible patients for the PRESERFLO&#x02122; MicroShunt should not have had incisional glaucoma surgery on the affected eye within the past [x] months</td><td align="left">Consensus not reached</td><td align="left"><p>1&#x000a0;month (0)</p><p>3&#x000a0;months (17)</p><p>6&#x000a0;months (50)</p></td><td align="left"><p>12&#x000a0;months (25)</p><p>Ever (8)</p></td><td align="left">Round&#x000a0;2</td></tr><tr><td align="left">To optimise surgical outcomes, eligible patients for the PRESERFLO&#x02122; MicroShunt should not have had cataract surgery on the affected eye within the past [x] months</td><td align="left">Consensus not reached</td><td align="left"><p>1&#x000a0;month (0)</p><p>3&#x000a0;months (33)</p><p>6&#x000a0;months (67)</p></td><td align="left"><p>12&#x000a0;months (0)</p><p>Ever (0)</p></td><td align="left">Round&#x000a0;2</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left">Single choice&#x02014;yes or no</th><th align="left">Consensus yes/no</th><th align="left">Percentage yes/no (%)<sup>a</sup></th><th align="left">Delphi questionnaire round</th></tr></thead><tbody><tr><td align="left" colspan="4">Should the following ocular anatomy/physiology be considered to determine if patients are suitable for the PRESERFLO&#x02122; MicroShunt? Please detail any specific considerations.</td></tr><tr><td align="left">&#x000a0;Endothelial cell count</td><td align="left">Yes</td><td align="left">82</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">&#x000a0;Condition of the conjunctiva</td><td align="left">Yes</td><td align="left">100</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">Do you give consideration to the anterior chamber depth (i.e. consider requirement for phacoemulsification) when assessing a patient prior to PRESERFLO&#x02122; MicroShunt implantation?</td><td align="left">Yes</td><td align="left">100</td><td align="left">Round&#x000a0;2</td></tr><tr><td align="left" colspan="4">Do you prepare a patient for the PRESERFLO&#x02122; MicroShunt implantation procedure in the same way as trabeculectomy, with regards to:</td></tr><tr><td align="left">&#x000a0;Frequency of preoperative patient visits</td><td align="left">Yes</td><td align="left">100</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">&#x000a0;Preoperative assessments and testing</td><td align="left">Yes</td><td align="left">91</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">&#x000a0;Preoperative steroid use</td><td align="left">Yes</td><td align="left">100</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">&#x000a0;Alteration in systemic anti-coagulant and anti-aggregant therapy</td><td align="left">Yes</td><td align="left">73</td><td align="left">Round&#x000a0;1</td></tr><tr><td align="left">&#x000a0;IOP-lowering medication drop holiday</td><td align="left">Yes</td><td align="left">100</td><td align="left">Round&#x000a0;1</td></tr></tbody></table><table-wrap-foot><p><italic>IOP</italic> intraocular pressure. Delphi round questionnaires were developed using the findings from the targeted literature review, input from the steering committee and feedback provided by the panellists during each round</p><p><sup>a</sup>Answers to Likert scale questions were provided on a six-point scale: strongly agree, agree, slightly agree, slightly disagree, disagree, or strongly disagree. For each Likert scale question, &#x02018;do not wish to answer&#x02019; or &#x02018;insufficient expertise&#x02019; options were also included. Consensus was set at a pre-defined threshold of at least 70% of panellists selecting &#x02018;Strongly disagree&#x02019;/&#x02018;Disagree&#x02019; or &#x02018;Strongly agree&#x02019;/&#x02018;Agree&#x02019; for six-point Likert scale questions, or at least 70% selecting the same option for multiple-choice questions. For Likert scale questions, &#x02018;Slightly agree&#x02019; and &#x02018;Slightly disagree&#x02019; were not included in the calculation of agreement/disagreement and therefore the overall percentage may not equal 100%</p><p><sup>b</sup>Statement was revised for round&#x000a0;2 and included in the postoperative section: &#x02018;The PRESERFLO&#x02122; MicroShunt implantation procedure has a reasonably predictable postoperative follow-up appointment schedule, with fewer unscheduled visits compared with trabeculectomy&#x02019;</p><p><sup>c</sup>Revised question for round&#x000a0;2: &#x02018;Although the target patient population from the PRESERFLO&#x02122; MicroShunt are patients with primary open-angle glaucoma, with no other underlying eye disorders, the device may also be suitable for patients with the following&#x02019;</p></table-wrap-foot></table-wrap></p><p id="Par2">The original article has been corrected.</p></sec></body></article>
